Fragile X Syndrome: Supportive Treatment, Unmet Needs, and Paths to Novel Interventions and Disease-Targeted Therapies.
FXS researchers are building collaborative consortia to fast-track supportive care improvements and rigorous clinical trials—get involved.
01Research in Context
What this study did
Berry-Kravis (2022) wrote a roadmap for fragile X syndrome (FXS) research. The paper lists what still needs fixing in care and trials.
It calls for team science. Big consortia should share data, pick agreed-upon tests, and run faster, smarter studies.
What they found
The review found the field is stuck. Good outcome tools exist, but studies use different ones and move too slowly.
The fix is to join the new FXS research hubs. Shared tests and plain-language consent will speed up supportive-care trials.
How this fits with other research
Berry-Kravis et al. (2008) and Falcomata et al. (2012) already gave FXS reliable cognitive and learning-platform tests. The 2022 paper folds those tools into its master plan.
Laugeson et al. (2014) showed that 94% of medical trials lock out people with ID. Berry-Kravis (2022) answers with concrete fixes—consortia, caregiver supports, and easy-read consent—so FXS studies can lead the way on inclusion.
Kaplan-Kahn et al. (2026) tweaks the PSI-SF parent stress form for preschool FXS/ASD families. The roadmap welcomes this tweak as part of its push for better parent-report measures.
Why it matters
If you serve kids or adults with FXS, you can now refer families to these growing research hubs. Clinics that join the consortia get first access to new outcome tools and faster evidence on what works. Push your site to adopt the shared battery—RBANS List Memory, NEPSY Tower, and the learning-platform test—so your data plug right into the big picture.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Email your local FXS research hub and ask to use the shared cognitive battery—RBANS List Memory plus NEPSY Tower—so your client data can feed the next big trial.
02At a glance
03Original abstract
Fragile X syndrome (FXS), as a monogenic cause of intellectual disability and autism spectrum disorder, has been one of the first neurodevelopmental disorders in which molecular and neuronal mechanisms of disease have been identified, leading to the concept of targeting the underlying disease to reverse symptoms. Translating findings in basic science and animal models to humans with FXS has proven difficult. These challenges have prompted the FXS field to organize to build interlocking projects to support initiatives to improve supportive care, make clinical research accessible to families, generate collaborative research on natural history and outcome measures, and create clinical trial consortia and novel trial designs.
American journal on intellectual and developmental disabilities, 2022 · doi:10.1352/1944-7558-127.2.90